Grassley Urges Trump Administration to Swiftly Finalize Rule Banning Over-the-Counter Kratom

Key facts

In a public statement issued on Oct. 2, 2026, Sen. Chuck Grassley called on executive branch officials in the Trump administration to execute pending administrative rules designed to restrict or prohibit the commercial trade of kratom. Grassley expressed strong opposition to the continued retail availability of the substance, asserting that all forms of kratom pose substantial danger to consumers.

The Iowa senator singled out everyday point-of-sale environments, contending that products containing kratom should be immediately removed from gas station counters, smoke shops, vape stores, and general retail outlets nationwide. His remarks were directed at pressuring federal administrative agencies to finalize proposed regulatory frameworks that would curtail over-the-counter sales.

Grassley’s urgent call reflects ongoing concern among lawmakers and public safety officials regarding the widespread accessibility of unapproved psychoactive substances sold alongside conventional consumer goods. By framing the issue as an immediate public health necessity, Grassley joined a broader coalition of critics calling for federal intervention against unregulated botanical compounds that interact with central nervous system pathways.

Why it matters

The call to restrict or eliminate legal access to kratom carries wide-ranging consequences across federal public health policy, commerce, law enforcement, and consumer safety. If the Trump administration responds by enacting a comprehensive federal ban or restrictive regulatory standard, it would fundamentally restructure the domestic market for botanical products and dietary supplements.

From a market perspective, kratom has grown into a lucrative multi-million-dollar industry in the United States. Thousands of independent vape shops, specialty smoke stores, gas station chains, and online vendors rely on kratom sales as a significant revenue driver. A federal rule shutting down these distribution channels would eliminate commercial inventories, disrupt supply chains originating primarily in Southeast Asia, and affect thousands of small and medium-sized retail enterprises.

For consumers, federal action would alter access for an estimated millions of Americans who report using kratom. Proponents and users frequently employ the plant for self-managing chronic pain, anxiety, depression, or symptoms of opioid withdrawal. Critics of prohibition argue that an immediate ban without approved therapeutic alternatives could drive consumers toward illicit street narcotics or dangerous unregulated black-market substitutes.

Conversely, public health advocates and toxicologists emphasize that the lack of federal oversight exposes consumers to severe hazards. Unregulated kratom products often vary wildly in potency and can contain synthetic alkaloid concentrates or harmful contaminants, including heavy metals, salmonella, or synthetic opioids. Establishing clear federal boundaries could mitigate toxic exposure, prevent accidental poisonings, and establish standardized regulatory authority over novel psychoactive compounds.

Kratom, scientifically designated as Mitragyna speciosa, is a tropical tree native to Southeast Asia, particularly Thailand, Indonesia, Malaysia, Myanmar, and Papua New Guinea. For centuries, populations in these regions have used the tree's leaves as a traditional herbal remedy, chewing raw leaves or brewing them into tea to alleviate physical fatigue during manual labor or to treat common ailments.

The physiological effects of kratom stem from its complex chemical profile, which includes more than 40 distinct alkaloids. The principal active constituents are mitragynine and 7-hydroxymitragynine. These compounds act as partial agonists at mu-opioid receptors in the central nervous system. At lower dosages, kratom produces mild stimulant effects, increasing alertness and physical energy. At higher doses, it exhibits typical opioid-like properties, delivering analgesia, sedation, and euphoria.

The federal regulatory history of kratom in the United States has been marked by acute institutional friction. In August 2016, the Drug Enforcement Administration (DEA) announced an emergency plan to temporarily place mitragynine and 7-hydroxymitragynine into Schedule I of the Controlled Substances Act, placing kratom in the same legal category as heroin and LSD. The DEA cited an influx of unapproved importations and a growing number of poison control center calls.

However, the 2016 proposal provoked unprecedented opposition from public advocacy groups, scientific researchers, and members of Congress. Critics argued that emergency scheduling would stifle scientific research into potential pain relief applications and criminalize millions of law-abiding citizens. In October 2016, the DEA took the extraordinarily rare step of withdrawing its notice of intent, opting instead to request a scientific and medical evaluation from the FDA and invite public feedback.

In the years following, the FDA maintained a strong warning posture against kratom. The agency issued repeated health advisories warning consumers against its use, citing risks of addiction, dependence, liver injury, seizures, and fatal overdoses, particularly when taken in combination with other drugs or alcohol. The FDA has consistently maintained that no prescription or over-the-counter drug products containing kratom have been approved as safe or effective for any medical usage.

Because federal authorities did not institute a complete statutory ban, individual states developed a patchwork of conflicting legal regimes. At least six states—including Alabama, Arkansas, Indiana, Rhode Island, Vermont, and Wisconsin—enacted state-level bans classifying kratom as a controlled substance. Conversely, several other states passed versions of the Kratom Consumer Protection Act (KCPA). These state laws permit adult sales while setting minimum age limits, mandating laboratory testing for contaminants and synthetic alkaloid spikes, requiring clear labeling, and establishing civil penalties for non-compliant vendors.

Reaction

Senator Grassley's demand draws clear lines between industry advocates, medical organizations, and regulatory bodies. Consumer advocacy organizations such as the American Kratom Association (AKA) have long pushed back against outright prohibitions, advocating instead for national KCPA standards. Industry groups argue that prohibition punishes responsible adult consumers while incentivizing an unregulated illicit trade, contending that federal policy should focus on removing adulterated products rather than natural leaf powder.

Medical and toxicological associations, alongside state poison control networks, have expressed support for stricter federal controls over over-the-counter psychoactive substances. Public health experts frequently cite the rising popularity of high-potency liquid kratom extracts and concentrated synthetic alkaloid shots sold in gas stations as a primary driver of acute poisonings and emergency room visits.

Within the executive branch, administrative agencies face procedural constraints under federal law. The Administrative Procedure Act requires agencies to undertake structured rulemaking processes, including public notice, interagency review, and scientific evaluation before finalizing major restrictions or scheduling decisions, making rapid administrative action subject to legal review.

What we don't know yet

Significant gaps remain regarding the precise administrative mechanism and scope of the proposed rule referenced by Sen. Grassley. The available public record does not specify whether the Trump administration is contemplating a full Schedule I classification through the DEA or targeted regulatory enforcement actions executed via FDA supplement rules.

Furthermore, it remains unclear whether proposed federal restrictions would draw technical distinctions between traditional, raw leaf botanical powder and high-potency concentrated extracts or synthetically altered 7-hydroxymitragynine products. The exact timeline for executive branch review, the formal publication date of any final administrative rule, and the designated federal enforcement strategy across state jurisdictions also remain unconfirmed.

What to watch

Moving forward, several key indicators will reveal the direction of federal kratom policy. Observers should watch the Federal Register for official notices or final rulemakings published by the FDA, DEA, or Department of Health and Human Services regarding controlled substance scheduling or supplement safety enforcement.

Additionally, formal policy statements or executive actions originating from the Trump administration will clarify the executive branch's enforcement priorities regarding over-the-counter psychoactive products. In Congress, track potential legislative initiatives or committee oversight hearings led by Grassley or federal health committees. Finally, monitor state legislatures during upcoming sessions to see if states pass additional localized bans or enact state-level consumer protection statutes while federal regulations remain under deliberation.

This report is based on original news coverage detailed by Joseph Choi.